



Small but heading for the big time

Nanobiotix joins the CAC® PME Index

Paris, France, 17 June, 2014 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces that the company was recently added to the CAC® PME Index. This was effective prior to the market opening on June 17, 2014.

Calculated in real time, the CAC® PME tracks the performance of between 20 and 40 French PEA PME eligible companies. Each stock, listed on Euronext or Alternext markets in Paris, has a capped weighting of 7.5% and should meet several criteria including turnover, total assets and liquidity amounts daily exchanged. For more information about the CAC® PME Index, including eligibility criteria, visit indices.euronext.com.

Laurent Levy, CEO of Nanobiotix commented: *“The integration of Nanobiotix in the CAC® PME Index is good news for the company and our shareholders. It should increase the stock visibility to other potential investors and helps us raise the company’s profile as it achieves future key milestones.”*

As a reminder, Nanobiotix is also included in the Next Biotech Index, the first and unique biotech index which helps investors, fund managers and issuers to track the performance of fast-growing biotech and innovative sector on a European scale. The Index includes 25 companies (listed on Euronext and Alternext). In May 2014, the market capitalization of the Next Biotech Index represented a total of €5.9 billion. At this value, this means that Euronext is the premier exchange group in the Eurozone, in terms of listed biotech companies and market capitalization.



About NANOBIOTIX – www.nanobiotix.com

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers (Soft Tissue Sarcoma, Breast Cancer, Liver Cancer, H&N cancer, Glioblastoma, Prostate...) via multiple routes of administration.

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The Company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

For more information, please contact:

Nanobiotix

Sarah Gaubert
Head of Communication and Public Affairs
+33 (0)1 40 26 07 55
contact@nanobiotix.com

Financial communication and investors relations

NewCap
Emmanuel Huynh/Louis-Victor Delouvrier
+33 (0)1 44 71 98 53
nano@newcap.fr



Media relations

France - **NewCap**
Annie-Florence Loyer
+33 (0)6 88 20 35 59
afloyer@newcap.fr

Outside France - **Instinctif Partners**
Melanie Toyne Sewell / Katherine Lynch
+44 (0) 207 457 2020
nanobiotix@instinctif.com